tropisetron has been researched along with Malignant-Carcinoid-Syndrome* in 2 studies
2 other study(ies) available for tropisetron and Malignant-Carcinoid-Syndrome
| Article | Year |
|---|---|
Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.
A 69-yr-old man with known carcinoid syndrome treated with octreotide and interferon-alpha 2b developed diarrhea, with six to eight watery to semiliquid stools per day. Diminished stool frequency and increased stool consistency were obtained by treatment with the 5-hydroxytryptamine-3 receptor antagonists ondansetron and tropisetron. Successful alleviation of the diarrhea was also observed with the alpha 2-receptor agonist clonidine. These observations indicate that these classes of drugs should be evaluated in a controlled trial in patients with carcinoid-associated diarrhea. Topics: Antiemetics; Clonidine; Diarrhea; Humans; Indoles; Male; Malignant Carcinoid Syndrome; Middle Aged; Ondansetron; Tropisetron | 1995 |
The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome.
Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome. Topics: Adult; Aged; Diarrhea; Female; Humans; Indoles; Injections, Intravenous; Male; Malignant Carcinoid Syndrome; Middle Aged; Serotonin Antagonists; Tropisetron | 1988 |